drugset / Trial / NCT07447141
DBM-1152A Inhalation Solution in Chinese Healthy Subjects
Phase 1
Completed
44 enrolled
Joincare Pharmaceutical Group Industry Co., Ltd
Livzon Pharmaceutical Group Inc. · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A Inhalation Solution in healthy Chinese adult subjects.
Timeline
- Start
- 2023-12-24
- Primary completion
- 2024-04-08
- Completion
- 2024-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBM-1152A | Unknown | 1 mg | Inhaled |
| Subject | DBM-1152A | Unknown | 2 mg | Inhaled |
| Subject | DBM-1152A | Unknown | 4 mg | Inhaled |
| Subject | DBM-1152A | Unknown | 6 mg | Inhaled |
| Subject | DBM-1152A | Unknown | 9 mg | Inhaled |
Indications
No indication recorded.